RxDoctor Payments DataLook up a doctor →

Cathy Payne

Acute Care · Phoenix, AZNPI 1285930925

Payments from drug & device makers

$26,038in general payments, 2019–2025

Across 628 payments — averaging $41.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$12K
  • Seagen Inc.$1K
  • AstraZeneca$994
  • Pfizer$823
  • Genentech USA, Inc.$802
  • E.r. Squibb & Sons, L.L.C.$765
  • plus $9K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation38$12,265
Seagen Inc.37$1,060
AstraZeneca(2 entities)42$994
Pfizer51$823
Genentech USA, Inc.28$802
E.r. Squibb & Sons, L.L.C.27$765
Bristol Myers Squibb37$680
Novartis36$641
Merck27$602
Amgen22$601
Johnson & Johnson(2 entities)28$598
Daiichi Sankyo Inc.14$432
Blueprint Medicines Corporation13$368
Astellas Pharma US Inc17$364
Sanofi17$344
EMD Serono, Inc.11$328
AbbVie16$285
Lilly USA, LLC12$279
Gilead(2 entities)7$238
Pharmacyclics LLC, An Abbvie Company10$231
Genmab U.S., Inc.5$228
Sumitomo Pharma America, Inc.2$202
Eisai Inc.9$194
Bayer10$188
Array Biopharma Inc11$176
Adaptive Biotechnologies Corporation7$175
GSK7$171
Tersera Therapeutics LLC5$142
Sobi, Inc3$136
Puma Biotechnology, Inc.6$126
Regeneron Healthcare Solutions, Inc.4$121
Karyopharm Therapeutics Inc.4$104
Rigel Pharmaceuticals, Inc.4$96
Syndax Pharmaceuticals, Inc.1$93
Takeda Pharmaceuticals U.S.A., Inc.3$87
Stemline Therapeutics Inc.4$86
Jazz Pharmaceuticals Inc.4$85
Exelixis Inc.4$79
Ipsen Biopharmaceuticals, Inc5$79
AVEO Pharmaceuticals, Inc.4$73
Morphosys, US Inc.3$57
G1 Therapeutics, Inc.2$43
Coherus Oncology, Inc.2$43
Springworks Therapeutics, Inc.2$39
Epizyme, Inc.2$38
Deciphera Pharmaceuticals Inc.2$38
Pharmaessentia USA Corporation2$36
Legend Biotech USA Inc.1$32
Kyowa Kirin, Inc.2$31
Mirati Therapeutics, Inc.2$30
Myovant Sciences Inc.2$29
EUSA Pharma (US) LLC1$25
Progenics Pharmaceuticals, Inc.1$23
CTI Biopharma Corp.1$22
ADC Therapeutics America, Inc.1$22
Servier Pharmaceuticals LLC1$22
Beigene USA, Inc.1$21
CSL Behring1$20
Global Blood Therapeutics, Inc.1$19
Clovis Oncology, Inc.1$19

How this compares

$26,038 in reported general payments places this provider in the 95th percentile of 482 acute care providers in Arizona.

See all acute care providers in Arizona →

Medicare billing

Part B allowed, 2024
$3,372
Medicare patients
38
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Phoenix

See the full list for Arizona →

Where these figures come from

Is this you, or does something look wrong? →